awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33414307-1D3CB471-F241-44EF-B930-2B5CC17BA350
Q33414307-1D3CB471-F241-44EF-B930-2B5CC17BA350
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33414307-1D3CB471-F241-44EF-B930-2B5CC17BA350
A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.
P2860
Q33414307-1D3CB471-F241-44EF-B930-2B5CC17BA350
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33414307-1D3CB471-F241-44EF-B930-2B5CC17BA350
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
fcfc5d854116dc67e338ba12a3dfd2968f958be8
P2860
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.